Patients with BAP1-mutant vs. those with PBRM1-mutant RCC have shorter survival (4.6 years, 95% CI 2.1–7.2 vs. 10.6 years, 95% CI 9.8–11.5; HR = 2.7; 95% CI 0.99–7.6, p = 0.044) (26, 66). This evidence concerns the gene PBRM1 and renal cell carcinoma.